JAK mutations as escape mechanisms to anti-PD-1 therapy

Aurelien Marabelle; Sandrine Aspeslagh; Sophie Postel-Vinay; Jean Charles Soria

doi:10.1158/2159-8290.CD-16-1439

JAK mutations as escape mechanisms to anti-PD-1 therapy

Aurelien Marabelle, Sandrine Aspeslagh, Sophie Postel-Vinay, Jean Charles Soria

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

24 Citations (Scopus)

Résumé

JAK mutations could be one of the primary escape mechanisms to anti-PD-1/PD-L1 immunotherapy via impaired IFNγsignaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments.

langue originale	Anglais
Pages (de - à)	128-130
Nombre de pages	3
journal	Cancer Discovery
Volume	7
Numéro de publication	2
Les DOIs	https://doi.org/10.1158/2159-8290.CD-16-1439
état	Publié - 1 févr. 2017

Accès au document

10.1158/2159-8290.CD-16-1439

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{0bd95bdb01314e5fb638f3a5b1039301,

title = "JAK mutations as escape mechanisms to anti-PD-1 therapy",

abstract = "JAK mutations could be one of the primary escape mechanisms to anti-PD-1/PD-L1 immunotherapy via impaired IFNγsignaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments.",

author = "Aurelien Marabelle and Sandrine Aspeslagh and Sophie Postel-Vinay and Soria, {Jean Charles}",

note = "Publisher Copyright: {\textcopyright} 2017 American Association for Cancer Research.",

year = "2017",

month = feb,

day = "1",

doi = "10.1158/2159-8290.CD-16-1439",

language = "English",

volume = "7",

pages = "128--130",

journal = "Cancer Discovery",

issn = "2159-8274",

number = "2",

}

TY - JOUR

T1 - JAK mutations as escape mechanisms to anti-PD-1 therapy

AU - Marabelle, Aurelien

AU - Aspeslagh, Sandrine

AU - Postel-Vinay, Sophie

AU - Soria, Jean Charles

PY - 2017/2/1

Y1 - 2017/2/1

N2 - JAK mutations could be one of the primary escape mechanisms to anti-PD-1/PD-L1 immunotherapy via impaired IFNγsignaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments.

AB - JAK mutations could be one of the primary escape mechanisms to anti-PD-1/PD-L1 immunotherapy via impaired IFNγsignaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments.

UR - http://www.scopus.com/inward/record.url?scp=85011933908&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-16-1439

DO - 10.1158/2159-8290.CD-16-1439

M3 - Article

C2 - 28167612

AN - SCOPUS:85011933908

SN - 2159-8274

VL - 7

SP - 128

EP - 130

JO - Cancer Discovery

JF - Cancer Discovery

IS - 2

ER -